Dr Angel Alsina is a Collaborative Professor of Surgery at the University of South Florida, Morsani College of Medicine and is the Director of the Liver Cancer Program at Tampa General Hospital, in Tampa Florida. A native of Puerto Rico, Dr Alsina pursued undergraduate studies at Boston College, his medical degree at Ponce Health Sciences, and surgical residency at St. Elizabeth’s Medical Center in Boston. He remained there to complete an ASTS-approved fellowship in multi-organ transplantation and hepatobiliary surgery at the New England Deaconess Hospital/ Harvard Department of Surgery. With over 23 years in liver transplantation, Dr Alsina has acquired broad expertise in transplantation, hepatic surgical disorders, hepatology, and hepato-oncology. He is a proven investigator in pivotal trials in liver transplantation, liver cancer, hepatitis C, and other hepatic disorders. He has published as primary author in topics of acute liver failure, liver malignancies, hepatocellular carcinoma, transplantation, cirrhosis and portal hypertension, ethnic and ethical aspects of transplantation, and liver oncology. He was instrumental in providing access to liver transplantation to undeserved patients from Puerto Rico. Dr Alsina oversees a large liver cancer program and manages systemic chemotherapy and the clinical trials of liver cancer. He has speaking experience nationally and is a national CME teacher in various fields. He was granted Fellowship designation by the AASLD in 2019. Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, Neff GW, Rosemurgy AS, Alsina AE. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2013 Jul;15(7):504-10 Naugler W, Alsina A, Frenette C, Rosssaro L, Sellers M. Building the Multidisciplinary Team for Management of Patients with Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2015 May;13(5):827-35 Alsina A, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, Kemmer N. Can sorafenib extends survival of recurrent hepatocellular carcinoma following liver transplantation? Am Surg 2014;80:680-4. Nakshabandi A, Franco E, Kemmer N, Alsina A. Successful liver transplantation for hyperammonemic fibrolamellar hepatocellular carcinoma: A case report. ACG Case Rep J 2016 Aug 17;3(4):e106 Leone P, Santos M, Finan J, Alsina A, Franco S. Liver transplantation recipient with malignant transformation of hepatic adenoma. Case Reports of Clin Pathol 2016;3:8-14. Alsina AE, Athienitis A, Nakshabandi A, Claudio RE, Aslam S, Arroyo J, Hillenberg I, Mallorga A, Lahoti M, Kemmer N. Outcomes of abdominal surgeries in cirrhotic patients performed by liver transplant surgeons: Are these safe? Am J Surg 2018; 216(3):518-523 Alsina A, Apple R, Kemmer R., Orlowski D. The malleability of transplant criteria: At what costs? Narrat Inq Bioeth 2019;9(1):77-82 Alsina AE, Alsina AA, Athienitis A, Buggs J, Aslam S, Kemmer N. Is Fulminant Hepatic Failure the Nemesis for Liver Transplant Centers? A Two Decade Psycho-Social and Long Term Outcomes Study. Am Surg 2018;1;84(7):1197-1203.

Prof. Angel Alsina has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies: